RecruitingNot Applicable

Velocity-Based Resistance Training in Kidney Transplant Recipients

Colombia12 participantsStarted 2025-10-29

Plain-language summary

This randomized controlled trial aims to evaluate the effects of velocity-based resistance training on renal function and metabolic health in kidney transplant recipients. Participants will be randomized into two groups performing resistance training at different execution velocities (maximal intended vs. submaximal controlled). The intervention will last 12 weeks and include multi-joint exercises (squat, bench press, military press). Primary outcomes include renal function (serum creatinine, eGFR, blood urea nitrogen, uric acid) and metabolic markers (HDL, triglycerides, glucose, waist circumference, blood pressure). Secondary outcomes include muscle strength, force-velocity profile, anthropometry, physical activity, fitness perception, and adherence to immunosuppressive medication.

Who can participate

Age range

18 Years – 50 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Men and women aged 18 to 50 years. * Kidney transplant performed ≥12 months before enrollment. * Stable graft function in the previous 6 months (serum creatinine \< 1.5 mg/dL, no rejection episodes). * Written medical clearance from a nephrologist to perform moderate-to-vigorous physical activity. * Signed informed consent. Exclusion Criteria: * Active autoimmune disorders. * Recent coronary disease (≤6 months). * Severe musculoskeletal limitations incompatible with resistance training. * Diagnosis of diabetes mellitus (pre- or post-transplant). * Current active infection. * Use of immunosuppressive drugs with contraindications for exercise (e.g., mTOR inhibitors at baseline).

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Serum creatinine (mg/dL) - change from baseline

Timeframe: Baseline and week 13 (after completion of 12-week intervention)

Estimated glomerular filtration rate (eGFR, mL/min/1.73 m²) - change from baseline

Timeframe: Baseline and week 13 (after completion of 12-week intervention)

Blood urea nitrogen (BUN, mg/dL) - change from baseline

Timeframe: Baseline and week 13 (after completion of 12-week intervention)

Serum Uric Acid (mg/dL)

Timeframe: Baseline and week 13 (after completion of 12-week intervention)

HDL cholesterol (mg/dL) - change from baseline

Timeframe: Baseline and week 13 (after completion of 12-week intervention)

Triglycerides (mg/dL) - change from baseline

Timeframe: Baseline and week 13 (after completion of 12-week intervention)

Fasting glucose (mg/dL) - change from baseline

Trial details

NCT IDNCT07370727

SponsorFundación Universitaria del Area Andina

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-06-01

View on ClinicalTrials.gov More Kidney Transplant Recipients trials

Plain-language summary

Who can participate

Age range

18 Years – 50 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Serum creatinine (mg/dL) - change from baseline

Timeframe: Baseline and week 13 (after completion of 12-week intervention)

Estimated glomerular filtration rate (eGFR, mL/min/1.73 m²) - change from baseline

Timeframe: Baseline and week 13 (after completion of 12-week intervention)

Blood urea nitrogen (BUN, mg/dL) - change from baseline

Timeframe: Baseline and week 13 (after completion of 12-week intervention)

Serum Uric Acid (mg/dL)

Timeframe: Baseline and week 13 (after completion of 12-week intervention)

HDL cholesterol (mg/dL) - change from baseline

Timeframe: Baseline and week 13 (after completion of 12-week intervention)

Triglycerides (mg/dL) - change from baseline

Timeframe: Baseline and week 13 (after completion of 12-week intervention)

Fasting glucose (mg/dL) - change from baseline